International trade · 18/04/2022

U.S. International Trade Commission Terminates Investigation into Adalimumab, Citing Settlement

The U.S. International Trade Commission has decided not to review an initial determination that terminated an investigation into adalimumab, following a settlement agreement, effectively ending the probe